Biomedical Engineering Reference
In-Depth Information
Pettengell, R., Luft, T., Henschler, R., Hows, J. M., Dexter, T. M., Ryder, D. and Testa, N. G.
1994. Direct comparison by limiting dilution analysis of long-term culture-initiating cells
in human bone marrow, umbilical cord blood, and blood stem cells. Blood 84:3653-9.
Pineault, N., Helgason, C. D., Lawrence, H. J. and Humphries, R. K. 2002. Differential
expression of Hox, Meis1, and Pbx1 genes in primitive cells throughout murine hemato-
poietic ontogeny. Exp Hematol 30:49-57.
Plimack, E. R., Kantarjian, H. M. and Issa, J. P. 2007. Decitabine and its role in the treatment
of hematopoietic malignancies. Leuk Lymphoma 48:1472-81.
Radich, J. P., Dai, H., Mao, M., Oehler, V., Schelter, J., Druker, B., Sawyers, C., Shah, N.,
Stock, W., Willman, C. L., Friend, S. and Linsley, P. S. 2006. Gene expression changes
associated with progression and response in chronic myeloid leukemia. Proc Natl Acad Sci
USA 103:2794-9.
Raza-Egilmez, S. Z., Jani-Sait, S. N., Grossi, M., Higgins, M. J., Shows, T. B. and Aplan, P.
D. 1998. NUP98-HOXD13 gene fusion in therapy-related acute myelogenous leukemia.
Cancer Res 58:4269-73.
Roeder, I., Horn, M., Glauche, I., Hochhaus, A., Mueller, M. C. and Loeffler, M. 2006.
Dynamic modeling of imatinib-treated chronic myeloid leukemia: functional insights and
clinical implications. Nat Med 12:1181-4.
Rowley, J. D. 1973. Letter: A new consistent chromosomal abnormality in chronic myelo-
genous leukaemia identified by quinacrine fluorescence and Giemsa staining. Nature
243:290-3.
Shah, N. P., Nicoll, J. M., Nagar, B., Gorre, M. E., Paquette, R. L., Kuriyan, J. and Sawyers,
C. L. 2002. Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to
the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic
myeloid leukemia. Cancer Cell 2:117-25.
Shah, N. P., Tran, C., Lee, F. Y., Chen, P., Norris, D. and Sawyers, C. L. 2004. Overriding
imatinib resistance with a novel ABL kinase inhibitor. Science 305:399-401.
Sieburg, H. B., Cho, R. H. and Muller-Sieburg, C. E. 2002. Limiting dilution analysis for
estimating the frequency of hematopoietic stem cells: uncertainty and significance. Exp
Hematol 30:1436-43.
Siminovitch, L., McCulloch, E. A. and Till, J. E. 1963. The distribution of colony-forming
cells among spleen colonies. J Cell Physiol 62:327-36.
Simmons, P. J., Levesque, J. P. and Haylock, D. N. 2001. Mucin-like molecules as modulators
of the survival and proliferation of primitive hematopoietic cells. Ann N Y Acad Sci
938:196-206; discussion 206-7.
Simon, M., Grandage, V. L., Linch, D. C. and Khwaja, A. 2005. Constitutive activation of the
Wnt/beta-catenin signalling pathway in acute myeloid leukaemia. Oncogene 24:2410-20.
Spangrude, G. J., Heimfeld, S. and Weissman, I. L. 1988. Purification and characterization of
mouse hematopoietic stem cells. Science 241:58-62.
Stevenson, F. K. and Caligaris-Cappio, F. 2004. Chronic lymphocytic leukemia: revelations
from the B-cell receptor. Blood 103:4389-95.
Strauss, A. C., Chu, S., Holyoake, T. and Bhatia, R. 2007. Effective induction of apoptosis in
chronic myeloid leukemia CD34+ cells by histone deacetylase inhibitor LAQ824 in
combination with imatinib. Blood 110:312a.
Sutherland, H. J., Eaves, C. J., Lansdorp, P. M., Thacker, J. D. and Hogge, D. E. 1991.
Differential regulation of primitive human hematopoietic cells in long-term cultures
maintained on genetically engineered murine stromal cells. Blood 78:666-72.
Talpaz, M., Shah, N. P., Kantarjian, H., Donato, N., Nicoll, J., Paquette, R., Cortes, J.,
O'Brien, S., Nicaise, C., Bleickardt, E., Blackwood-Chirchir, M. A., Iyer, V., Chen, T. T.,
Huang, F., Decillis, A. P. and Sawyers, C. L. 2006. Dasatinib in imatinib-resistant
Philadelphia chromosome-positive leukemias. N Engl J Med 354:2531-41.
Terpstra, W., Ploemacher, R. E., Prins, A., van Lom, K., Pouwels, K., Wognum, A. W.,
Wagemaker, G., Lowenberg, B. and Wielenga, J. J. 1996. Fluorouracil selectively spares
